Navigation Links
Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
Date:9/25/2008

s and senior vice president of sales and marketing of Genentech;

-- Chief Science and Medical Officer: Michael R. Bristow, MD, PhD, current chairman and CSMO at ARCA and former CSMO at Myogen;

-- Executive Vice President of Commercial Operations: Randall St. Laurent, current EVP of commercial operations at ARCA and former vice president of commercial development at Scios;

-- Vice President of Marketing: James Carr, current VP of marketing at ARCA who was instrumental in the successful commercialization of Coreg, a leading beta-blocker treatment for heart failure; and

-- The combined company's board of directors will include Dr. Bristow, Mr. Brewer, Dr. J. William Freytag, Dr. Jean-Francois Formela and John Zabriskie from ARCA's current board, and Dr. Ted W. Love, Dr. Burton E. Sobel, and Mary K. Pendergast from Nuvelo's current board. Dr. Bristow will serve as chairman of the board.

Terms of the Proposed Transaction

Under the terms of the definitive merger agreement between Nuvelo, ARCA and Dawn Acquisition Sub, Inc., a wholly owned subsidiary of Nuvelo, Dawn Acquisition Sub will be merged with and into ARCA and ARCA will become a wholly owned subsidiary of Nuvelo. Under the agreement, Nuvelo will issue new shares of its common stock to ARCA common and preferred stockholders and assume outstanding options and warrants to acquire capital stock of ARCA such that these stockholders, option holders and warrant holders are expected to own or have the right to acquire approximately 67 percent of the common stock of the combined company on a fully-diluted basis, using the treasury stock method. Current Nuvelo stockholders are expected to own approximately 33 percent of the common stock of the combined company on a fully-diluted basis, using the treasury stock method.

The boards of directors of both Nuvelo and ARCA have approved the definitive merger agreement. The transaction is structured as a tax-free reorganization for fe
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers
2. Nuvelo Reports Second Quarter 2008 Financial Results
3. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
4. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
5. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
6. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
7. China Biopharma Effects 1 for 100 Reverse Stock Split
8. Top Biopharma Company Adopts BioFortis Translational Research Software for Centralized Management and Mining of Clinical Biomarker Data
9. Therapure Biopharma Inc. opens for business with first client contracts
10. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
11. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... (PRWEB) April 16, 2015 Capillus, ... distribution and physician network in Europe and Asia. ... has appointed Fernando Bermúdez, former Business Development Director ... An industry veteran, Mr. Bermúdez’s professional achievements include ... in Spain, while also penetrating the Portuguese marketplace ...
(Date:4/16/2015)... OncoTAb, Inc., a ... spin-out company, announced today the appointment of physician ... Chief Operating Officer (COO). Cooper brings to OncoTAb ... clinical diagnostic and biotechnology platforms in the fields ... extensive career transcends the field of medical and ...
(Date:4/16/2015)... 2015 /CNW/ - Bioenterprise Corporation is pleased to announce that ... Charlottetown , PEI.  Bioenterprise has established a ... Council for the commercialization of agricultural technologies and innovations. ... PEI ADAPT.  They have been at the heart of ... explains Dave Smardon , President & CEO of ...
(Date:4/16/2015)... -- Avelas Biosciences, an in vivo cancer ... that it has initiated a Phase 1b study of ... primary, non-recurrent breast cancer undergoing surgery. In commencing the ... Steven Chen , M.D., as vice president of ... study will enroll up to 39 women with stage ...
Breaking Biology Technology:Capillus, LLC Extends Laser Hair Therapy Products to Europe and Asia 2OncoTAb Names Dr. David L. Cooper as COO 2Bioenterprise Corporation Expands into the Maritimes 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3
... NOVEMBER 4, 2008, SAN DIEGO, Oct. 27 ... Kevin Gorman, President and Chief,Executive Officer of Neurocrine Biosciences ... in New York., The live presentation takes place ... /7:00 a.m. Pacific Time (PT). The presentation will,be simultaneously ...
... at 4:30 p.m. ET -, SOUTH SAN FRANCISCO, ... ) today reported financial results for the,quarter ended September ... million for the third quarter of,2008, 55% higher than ... was driven by revenue from Trofile(TM) for selecting HIV ...
... Lead Epidemiologist, RALEIGH, N.C., Oct. 27 ... the appointment of Dr.,Jerome Wilson as Senior Medical ... Dr. Wilson is responsible for providing consulting,services and ... provides extensive Phase IV Post-Marketing services to,pharmaceutical and ...
Cached Biology Technology:Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference 2Monogram Announces 2008 Third Quarter Financial Results 2Monogram Announces 2008 Third Quarter Financial Results 3Monogram Announces 2008 Third Quarter Financial Results 4Monogram Announces 2008 Third Quarter Financial Results 5Monogram Announces 2008 Third Quarter Financial Results 6Monogram Announces 2008 Third Quarter Financial Results 7Monogram Announces 2008 Third Quarter Financial Results 8Monogram Announces 2008 Third Quarter Financial Results 9Monogram Announces 2008 Third Quarter Financial Results 10Monogram Announces 2008 Third Quarter Financial Results 11Monogram Announces 2008 Third Quarter Financial Results 12Monogram Announces 2008 Third Quarter Financial Results 13Monogram Announces 2008 Third Quarter Financial Results 14Monogram Announces 2008 Third Quarter Financial Results 15Jerome Wilson Joins PRA International's Late Phase Service Group 2
(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has ... Strategic Business Report" report to their offering. ... US$ Thousands. The report provides separate comprehensive analytics for the ... , Europe , Asia-Pacific ... Latin America . Annual estimates and forecasts ...
(Date:3/17/2015)... 17, 2015 MedNet Solutions , ... clinical study management systems, is pleased to announce ... ARENA,s Outsourcing in Clinical Trials Southeast conference – ... an excellent forum for MedNet to showcase ... software-as-a-service (SaaS) eClinical technology platform. We ...
(Date:3/16/2015)... March 16, 2015 Between ... will present groundbreaking innovations in biometric identification at ... .      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ... innovation is well at the forefront: the company,s ... made in Germany . BiometricGate ...
Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3
... in Denmark revealed that increasing levels of non-fasting triglycerides ... in men and women. Higher cholesterol levels were associated ... this novel, 33-year study are now available online in ... Wiley-Blackwell on behalf of the American Neurological Association. ...
... decoded the DNA of the parasitic worm that causes ... pork or carnivorous wild game animals, such as bear ... Washington University School of Medicine in St. Louis and ... the parasite, Trichinella spiralis , which provide potential ...
... to different climates and diets as they split off from other ... for humans living today? A panel of scholars from ... Sunday February 20th at the AAAS meeting in Washington, DC, as ... at Work In Humans and Their Relatives." The speakers ...
Cached Biology News:Increasing triglyceride levels linked to greater stroke risk 2Trichinosis parasite gets DNA decoded 2Panelists to discuss evolution of human brain size, skin color and diet at AAAS meeting 2
... provide two highly efficient methods of identifying ... preparation. By using the large-scale screen method ... do is to transfer partial colonies of ... plates into the solutions provided by the ...
GLP-1 (HYB 147-12)...
... KLH-conjugated, synthetic peptide corresponding ... of mouse p19ARF. The ... acids 62-75. Clone 5-C3-1. ... by immunoblot. Stability ...
EDTA, tetrasodium salt, 1 kg. Ethylene diaminetetraacetic acid.Dihydrate. Assay: 99-101% (as is).Risks: 36, 37, 38 ; Safety Precautions: 22, 36, 37. Category: Nucleotides & Enzymes & Biochemicals, Ul...
Biology Products: